suramin has been researched along with Brain Neoplasms in 14 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study the effect of suramin on tumor growth, vascularity and oxygenation of a human glioma xenografted in the nude mouse was examined." | 7.70 | Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. ( Bakker, JH; Bernsen, HJ; Boerman, RH; Peters, JP; Rijken, PF; van der Kogel, AJ; Wesseling, P, 1999) |
| "The growth of human cerebral meningiomas depends on various growth factors, including epidermal growth factor (EGF), transforming growth factor (TGF)-alpha and TGF-beta, platelet-derived growth factor (PDGF)-BB, insulin-like growth factor (IGF)-I and IGF-II, and acidic and basic fibroblast growth factors." | 7.69 | Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. ( Adams, EF; Bickel, A; Fahlbusch, R; Gauer, S; Hren, J; Kiesewetter, F; Schrell, UM, 1995) |
| "Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance." | 6.71 | Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. ( Carson, KA; Gilbert, MR; Grossman, SA; Hochberg, FH; Laterra, JJ; Lesser, GJ, 2004) |
| "Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast growth factor (bFGF), to their receptors." | 5.29 | Suramin inhibits glioma cell proliferation in vitro and in the brain. ( Brem, S; Engelhard, H; Gately, S; Takano, S; Tsanaclis, AM, 1994) |
| "In this study the effect of suramin on tumor growth, vascularity and oxygenation of a human glioma xenografted in the nude mouse was examined." | 3.70 | Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. ( Bakker, JH; Bernsen, HJ; Boerman, RH; Peters, JP; Rijken, PF; van der Kogel, AJ; Wesseling, P, 1999) |
| "The growth of human cerebral meningiomas depends on various growth factors, including epidermal growth factor (EGF), transforming growth factor (TGF)-alpha and TGF-beta, platelet-derived growth factor (PDGF)-BB, insulin-like growth factor (IGF)-I and IGF-II, and acidic and basic fibroblast growth factors." | 3.69 | Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop. ( Adams, EF; Bickel, A; Fahlbusch, R; Gauer, S; Hren, J; Kiesewetter, F; Schrell, UM, 1995) |
| "Suramin is a polysulfonated naphthylurea that inhibits the function of growth factors and growth factor receptors implicated in glioma progression, angiogenesis, and radioresistance." | 2.71 | Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study. ( Carson, KA; Gilbert, MR; Grossman, SA; Hochberg, FH; Laterra, JJ; Lesser, GJ, 2004) |
| "Suramin is a novel anticancer agent that blocks the binding of growth factors, including basic fibroblast growth factor (bFGF), to their receptors." | 1.29 | Suramin inhibits glioma cell proliferation in vitro and in the brain. ( Brem, S; Engelhard, H; Gately, S; Takano, S; Tsanaclis, AM, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (64.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singla, AK | 1 |
| Bondareva, A | 1 |
| Jirik, FR | 1 |
| Nie, H | 1 |
| Fu, Y | 1 |
| Wang, CH | 1 |
| Laterra, JJ | 1 |
| Grossman, SA | 1 |
| Carson, KA | 1 |
| Lesser, GJ | 1 |
| Hochberg, FH | 1 |
| Gilbert, MR | 1 |
| Bellinzona, M | 1 |
| Roser, F | 1 |
| Matthies, C | 1 |
| Samii, M | 1 |
| Saini, M | 1 |
| Takano, S | 2 |
| Gately, S | 1 |
| Engelhard, H | 1 |
| Tsanaclis, AM | 1 |
| Brem, S | 1 |
| Schrell, UM | 1 |
| Gauer, S | 1 |
| Kiesewetter, F | 1 |
| Bickel, A | 1 |
| Hren, J | 1 |
| Adams, EF | 1 |
| Fahlbusch, R | 1 |
| Westphal, M | 2 |
| Hamel, W | 1 |
| Zirkel, D | 1 |
| Herrmann, HD | 2 |
| Bilzer, T | 1 |
| Reifenberger, G | 1 |
| Schober, R | 1 |
| Wechsler, W | 1 |
| Albert, FK | 1 |
| Behnke, J | 1 |
| Olson, JJ | 1 |
| Polk, DM | 1 |
| Reisner, A | 1 |
| Chen, BC | 1 |
| Lee, CM | 1 |
| Lin, WW | 1 |
| Johnson, JP | 1 |
| Bruce, JN | 1 |
| Sullivan, KA | 1 |
| Kim, B | 1 |
| Buzdon, M | 1 |
| Feldman, EL | 1 |
| Bernsen, HJ | 1 |
| Rijken, PF | 1 |
| Peters, JP | 1 |
| Bakker, JH | 1 |
| Boerman, RH | 1 |
| Wesseling, P | 1 |
| van der Kogel, AJ | 1 |
| Ackermann, E | 1 |
| Hoppe, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Suramin and Concurrent Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme[NCT00004073] | Phase 2 | 54 participants (Anticipated) | Interventional | 1999-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for suramin and Brain Neoplasms
| Article | Year |
|---|---|
[Anti-angiogenesis treatment for brain tumors--present and future].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Clinical Tr | 2005 |
Angiogenesis in human gliomas: prognostic and therapeutic implications.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cyclohexanes; Endothelial Growth Factors; Epidermal | 1997 |
2 trials available for suramin and Brain Neoplasms
| Article | Year |
|---|---|
Suramin and radiotherapy in newly diagnosed glioblastoma: phase 2 NABTT CNS Consortium study.
Topics: Aged; Brain Neoplasms; Confidence Intervals; Female; Follow-Up Studies; Glioblastoma; Humans; Male; | 2004 |
Epidermal growth factor receptor expression in human malignant glioma: in vitro and in vivo effects of application of monoclonal antibodies to the epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Neoplasm; Brain Neoplasms; Cell Division; Epidermal Growth Facto | 1994 |
10 other studies available for suramin and Brain Neoplasms
| Article | Year |
|---|---|
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Lin | 2014 |
Paclitaxel and suramin-loaded core/shell microspheres in the treatment of brain tumors.
Topics: Animals; Apoptosis; Biological Assay; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Luminescent | 2010 |
Biopolymer-mediated suramin chemotherapy in the treatment of experimental brain tumours.
Topics: Animals; Antineoplastic Agents; Biopolymers; Brain Neoplasms; Drug Implants; Drug Screening Assays, | 2004 |
Suramin inhibits glioma cell proliferation in vitro and in the brain.
Topics: Animals; Brain Neoplasms; Cell Division; Dose-Response Relationship, Drug; Drug Screening Assays, An | 1994 |
Inhibition of proliferation of human cerebral meningioma cells by suramin: effects on cell growth, cell cycle phases, extracellular growth factors, and PDGF-BB autocrine growth loop.
Topics: Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Division; DNA; Dose-Response Relationship, Drug | 1995 |
The efficacy and distribution of suramin in the treatment of the 9L gliosarcoma.
Topics: Animals; Brain Neoplasms; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Dose-Respo | 1994 |
Inhibition of ecto-ATPase by PPADS, suramin and reactive blue in endothelial cells, C6 glioma cells and RAW 264.7 macrophages.
Topics: Adenosine Triphosphatases; Animals; Brain Neoplasms; Cell Line; Endothelium, Vascular; Enzyme Inhibi | 1996 |
Suramin disrupts insulin-like growth factor-II (IGF-II) mediated autocrine growth in human SH-SY5Y neuroblastoma cells.
Topics: Brain Neoplasms; Cell Division; Glucose-6-Phosphate Isomerase; Humans; Insulin-Like Growth Factor II | 1997 |
Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.
Topics: Animals; Antineoplastic Agents; Blood Vessels; Brain Neoplasms; Glioma; Humans; Hypoxia; Mice; Mice, | 1999 |
Receptors for platelet derived growth factor in human glioma cell lines and influence of suramin on cell proliferation.
Topics: Brain Neoplasms; Cell Division; Cell Line; Glioma; Humans; Neoplasm Proteins; Platelet-Derived Growt | 1991 |